Physician profile
Nancy T Behram
NPI 1902895063
$3,382.77
in general payments reported to CMS, 2019-2025
39 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $289 · 2021: $899 · 2022: $815 · 2023: $485 · 2024: $309 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $448.98 | 2021-2023 | Ova1 |
| Abbvie INC. | $445.96 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Astellas Pharma US INC | $303.11 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $293.20 | 2019-2022 | |
| Hologic Sales and Service, LLC | $136.52 | 2020-2025 | Aptima, Novasure, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $127.64 | 2019-2025 | Paragard T 380a, Summit Doppler, Mara Console |
| Pfizer INC. | $125.15 | 2022-2024 | |
| Renovia INC | $119.55 | 2021 | |
| Novo Nordisk INC | $109.00 | 2023-2025 | Wegovy, Saxenda |
| Myriad Women'S Health, INC. | $90.75 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.97 | 2019-2022 | |
| Lilly USA, LLC | $86.21 | 2025 | Zepbound |
| Sumitomo Pharma America, INC. | $73.85 | 2023-2024 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $72.41 | 2019-2022 | |
| Myovant Sciences INC. | $69.32 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.64 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $56.39 | 2020-2022 | |
| Organon LLC | $54.44 | 2021-2022 | |
| Evofem Biosciences, INC. | $54.28 | 2021-2022 | |
| Sage Therapeutics, LLC | $53.04 | 2022-2023 | |
| Becton, Dickinson and Company | $45.13 | 2022 | |
| Avion Pharmaceuticals | $42.37 | 2020-2022 | |
| Innovation Technologies INC | $41.19 | 2021 | |
| Mayne Pharma Commercial LLC | $39.07 | 2022-2023 | |
| Allergan, INC. | $37.46 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $34.28 | 2019-2020 | |
| Baxter Healthcare | $31.80 | 2021 | |
| Vertical Pharmaceuticals, LLC | $26.73 | 2019 | |
| Optumhealth Care Solutions, LLC | $26.27 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Exact Sciences Corporation | $23.96 | 2023 | Cologuard Collection Kit |
| Scynexis, INC. | $22.98 | 2022 | |
| Mission Pharmacal Company | $22.81 | 2020 | |
| Avanos Medical | $20.80 | 2021 | |
| Lupin INC. | $19.40 | 2019 | |
| Solventum Corporation | $19.06 | 2024 | Prevena |
| Currax Pharmaceuticals LLC | $17.93 | 2022 | |
| Roche Diagnostics Corporation | $17.37 | 2019 | |
| Millicent US INC | $14.41 | 2019 | |
| Meditrina | $13.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Behram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.